Tag: Apnimed
In brief: Sunrise acquisition, sleep apnea survey, standing letter, IV shortage
October 11, 2024HME News Staff
FRESNO, Calif. – Sunrise Medical has acquired Nuprodx, a California-based manufacturer of bathroom mobility products, including a patented shower tub slider system for mobility impaired users.
The acquisition strengthens Sunrise Medical’s portfolio by adding Nuprodx’s bathroom mobility solutions to its existing broad range of assistive mobility solutions.
“Nuprodx’s innovative bathroom mobility products perfectly align with our mission...
Survey shows ‘devastating’ impact of sleep apnea
October 10, 2024HME News Staff
CAMBRIDGE, Mass. – Two-thirds of respondents said exhaustion from obstructive sleep apnea affects their ability to be present with loved ones, according to a new survey from Apnimed.
The company’s Sleep Health Inquiries on Needs and Emotions (SHINE), which surveyed 1,500 people living with OSA, found:
74% reported feeling worn out or exhausted from fatigue
67% reported fearing long-term health consequences
34% reported fearing...
Apnimed makes critical additions to C-suite
January 22, 2024HME News Staff
CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea and related disorders, has named Graham Goodrich as chief commercial officer and Ted Harding as chief human resources officer. The company says the additions to the C-suite are critical as the company prepares to launch AD109, a potential nighttime oral treatment currently in Phase 3. “We are thrilled to have attracted two...
In brief: Medline’s appetite, Apnimed’s joint venture
November 21, 2023HME News Staff
NORTHFIELD, Ill. – Medline has launched a new Food Benefit Solution that allows Medicare Advantage and Managed Medicaid Organizations to offer locally sourced and fresh produce, healthy groceries and prepared meals – delivered directly to member homes – as an added supplemental benefit.
“Access to a food benefit can help members meet their nutritional needs, encourage healthier eating habits, and manage and prevent chronic diseases,” said Amy Rogers, BSN, RN,...
Apnimed enters JV with Shionogi
November 20, 2023HME News Staff
CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacological therapies for the treatment of obstructive sleep apnea, has announced a joint venture with Shionogi & Co., a pharmaceutical company based in Japan, to develop therapies to treat OSA and other sleep disorders. The joint venture, Shionogi-Apnimed Sleep Science, combines Apnimed’s deep knowledge of OSA, highly experienced clinical-stage drug development team and robust network of...
Apnimed appoints Yee as senior exec
September 20, 2023HME News Staff
CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea and related disorders, has appointed John Yee, MD, MPH, as senior vice president of medical affairs. Dr. Yee will lead Apnimed’s efforts to engage and inform the clinical community about the company’s lead drug candidate AD109, as well as other pipeline assets, as they progress through clinical development toward commercial launch....
Apnimed secures additional financing
January 3, 2023HME News Staff
CAMBRIDGE, Mass. – Apnimed has secured $79.75 million in an oversubscribed financing round that extends its Series C financing to a total of $142.25 million. The company will use proceeds to fund the planned Phase 3 trials for its lead candidate, AD 109 (aroxybutynin + atomoxetine), which has the potential to be the first oral treatment for obstructive sleep apnea. “This substantial additional investment is a significant vote of confidence by our investors,” said Larry Miller, M.D.,...
Apnimed looks forward to Phase 3 studies
October 17, 2022HME News Staff
CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, has announced positive topline results from the MARIPOSA Phase 2b trial – an efficacy, safety and dose-finding study of one-month duration. The results were positive for the company’s lead candidate for OSA, AD109 (atomoxetine + aroxybutynin). The primary endpoint showed a statistically significant...
Apnimed secures funding for OSA treatment
May 5, 2022HME News Staff
CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has raised $62.5 million of committed capital in a Series C financing led by new investor Sectoral Asset Management. “Patients with obstructive sleep apnea are in need of new pharmaceutical treatment options to manage this serious, life-altering, and life-threatening disease,” said Larry Miller, M.D., CEO...
Apnimed treatment shows reduction in AHI
November 17, 2021HME News Staff
CAMBRIDGE, Mass. – Apnimed, a pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has announced positive topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, three-period crossover study (protocol APX-001) in patients with OSA evaluating AD504 and AD182. Patients treated with AD504 (atomoxetine plus trazodone) showed a strong trend in the reduction in AHI from placebo, which...